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Summary
Cyclooxygenase-derived prostaglandin E2 (PGE2) is the predominant prostanoid found in most colorectal cancers (CRC)
and is known to promote colon carcinoma growth and invasion. However, the key downstream signaling pathways necessary
for PGE2-induced intestinal carcinogenesis are unclear. Here we report that PGE2 indirectly transactivates PPAR through
PI3K/Akt signaling, which promotes cell survival and intestinal adenoma formation. We also found that PGE2 treatment of
Apcmin mice dramatically increased intestinal adenoma burden, which was negated in Apcmin mice lacking PPAR. We
demonstrate that PPAR is a focal point of crosstalk between the prostaglandin and Wnt signaling pathways which results
in a shift from cell death to cell survival, leading to increased tumor growth.
Introduction There is both pharmacologic and genetic evidence support-
ing the hypothesis that NSAIDs reduce colorectal cancer risk
Colorectal cancer (CRC) leads to significant cancer-related mor- via inhibition of COX-2 (Gupta and DuBois, 2001). For example,
bidity and mortality in most industrialized countries. Chronic levels of the COX-2 enzyme are elevated in a large percentage
use of nonsteroidal anti-inflammatory drugs (NSAIDs) and other of colorectal adenomas and adenocarcinomas (Eberhart et al.,
cyclooxygenase (COX) inhibitors is known to reduce the risk 1994), and COX-2 selective inhibitors have potent antitumor
for CRC in humans (Turini and DuBois, 2002). Identifying the effects in several different animal models of colorectal cancer
(Chulada et al., 2000; Jacoby et al., 2000; Oshima et al., 1996;molecular mechanisms underlying the protective effects of
NSAIDs and selective COX inhibitors is important, since this may Prescott and Fitzpatrick, 2000; Reddy et al., 2000; Sheng et al.,
1997). Moreover, forced overexpression of COX-2 in intestinalreveal other potential molecular targets for cancer prevention or
treatment. There are two cyclooxygenase isoforms, COX-1 and epithelial cells results in resistance to apoptosis and increased
cell adhesion to extracellular matrix (Tsujii and DuBois, 1995).COX-2, and both catalyze the conversion of arachidonic acid
(AA) to endoperoxide intermediates that are ultimately converted Finally, deletion of the COX-2 gene results in a marked decrease
of adenoma burden in both the small and large intestine into prostaglandins (PGE2, PGD2, PGF2, PGI2, and TxA2) by spe-
cific PG synthases (DuBois et al., 1998). COX-1 is constitutively Apc716 mutant mice (Oshima et al., 1996) and in Apcmin mice
(Chulada et al., 2000).expressed in most cells and tissues under normal circum-
stances. Conversely, COX-2 is usually absent from most tissues Although there is strong evidence to support a pro-onco-
genic role for COX-2 in colorectal carcinogenesis, the molecularor expressed at very low levels, but is highly induced in response
to inflammatory mediators, growth factors, oncogene activation, mechanism(s) by which the enzyme promotes tumor formation
is less clear. Recent evidence points to an important role forand tumor promoters (DuBois et al., 1998).
S I G N I F I C A N C E
Long-term use of cyclooxygenase (COX) inhibitors in humans leads to a 50% decrease in risk for colorectal cancer. It is not clear
precisely how COX-2-derived prostaglandins induce intestinal adenoma formation or the key downstream signaling pathways
required for these effects. This report demonstrates a novel link between the COX-2 derived PGE2 and Wnt/-catenin/Tcf signaling
pathways that is crucial in regulating intestinal adenoma burden, and provides in vivo proof that PGE2 regulates colorectal tumor
growth. Furthermore, our study demonstrates that PPAR is required for PGE2 to stimulate colorectal adenoma growth. These results
support the rationale for considering the development of PPAR antagonists for use in cancer prevention and/or treatment.
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the downstream metabolite PGE2 in COX-2-mediated tumor Apcmin mice available. We recently demonstrated that PPAR
activation by a high-affinity, subtype-selective agonist signifi-promotion. PGE2 levels are elevated in human colorectal cancers
and adenomas in familial adenomatous polyposis (FAP) patients cantly increases the number and size of small intestinal polyps
in Apcmin mice (Gupta et al., 2004). These findings suggest that(Giardiello et al., 2004; Mahmoud et al., 1999; Pugh and Thomas,
1994; Rigas et al., 1993). Exposure of CRC cells to PGE2 in vitro while removing the Ppard gene has little effect, activation of
PPAR signaling plays a major role in accelerating intestinalresults in protection against programmed cell death (Sheng et
al., 1998) and an increase in both cell proliferation and migration polyp formation in vivo.
Since PGE2 and PPAR are known to both promote cell(Sheng et al., 2001b). Studies in humans revealed that adenoma
regression was more effective when tissue PGE2 levels were survival and affect carcinoma growth in vitro, we tested the
hypothesis that the ability of PGE2 to accelerate adenomatousdramatically reduced following NSAID treatment (Giardiello et
al., 2004). Finally, genetic studies using mice lacking the PGE2 polyp growth was dependent on PPAR. PGE2 upregulated
PPAR transcriptional activity via activation of PI3K-Akt that ledcell surface receptors EP1, EP2, or EP4 point to an important
role for all three receptors in intestinal polyp formation (Mutoh to increased cell survival. The antiapoptotic effect of PGE2 was
negated in cells expressing a dominant-negative PPARprotein.et al., 2002; Sonoshita et al., 2001; Watanabe et al., 1999).
However, the in vivo role of PGE2 in promoting intestinal tumor Most importantly, PGE2 was found to promote intestinal epithe-
lial cell survival and colorectal adenoma growth in Apcmin, butgrowth remains unclear, but PGE2 is known to regulate cell
proliferation and apoptosis. not PPAR//Apcmin, mice. Collectively, our results identify
PPAR as a critical downstream mediator in PGE2-stimulatedPeroxsiome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors that are members of the promotion of colorectal tumor growth.
nuclear hormone receptor superfamily (Willson et al., 2000).
Putative endogenous ligands for PPARs include certain fatty Results
acids and fatty acid metabolites. Three distinct PPAR isoforms
(, /, and ) have been isolated and characterized. The PPAR PGE2 enhances PPAR transcriptional
activity via PI3K/Akt and  subtypes play essential roles in fatty acid catabolism
and storage. Emerging evidence suggests that the PPAR/ As a first step in testing the hypothesis that PGE2 promotes
CRC growth via PPAR, we determined the ability of PGE2 tosubtype is important for embryo implantation (Lim et al., 1999)
and fatty acid oxidation (Wang et al., 2003), and as a regulator affect PPAR transcriptional activity. We utilized LS-174T hu-
man colon carcinoma cells for these experiments, since theseof cell survival in both the kidney following hypertonic stress
(Hao et al., 2002) and in the skin following wound injury (Di-Poi cells express EP4 receptors (Sheng et al., 2001b) and produce
very little endogenous PGE2 (0.13 ng/105 cells) compared toet al., 2002, 2003).
There are also data linking PPAR to CRC. For example, HCA-7 cells (4.2 ng/105 cells) (Shao et al., 2000). LS-174T cells
were transfected with the PPRE3-tk-luciferase reporter vectorPPAR is overexpressed in a high percentage of colorectal can-
cers (Gupta et al., 2000; He et al., 1999). Furthermore, Wnt/ in which luciferase gene expression is driven by three tandem
repeats of the PPAR-response element (PPRE) from the acyl-APC/-catenin and K-Ras, two signaling pathways that are
commonly affected during CRC development, directly regulate CoA oxidase gene. A dose-dependent increase in luciferase
activity (representing activation of endogenous PPAR receptor)PPAR expression. A majority of colorectal cancers contain
inactivating mutations in the APC gene; a major consequence was seen with either a high-affinity, subtype-selective synthetic
ligand for PPAR (GW1516) (Figure 1A) or PGE2, but not withof this inactivation is increased expression of pro-oncogenic
genes (e.g., c-MYC and cyclin D1) via the -catenin/T cell fac- PGA2 or PGF2 (Figure 1B). Surprisingly, cotreatment of PGE2
and GW1516 has synergistic effects resulting in a dramatictor-4 (TCF-4) transcriptional complex (He et al., 1998). PPAR
is also a target of the APC/-catenin pathway (He et al., 1999). increase in PPAR transactivation (Figure 1C). Because all three
PPAR subtypes can bind to and activate this PPRE reporter,Restoration of wild-type APC in human colon cancer cells leads
to a decrease in PPAR levels, and mutant -catenin activates PGE2 could mediate its effects through any of the three PPAR
subtypes. To determine the subtype selectivity of this response,the PPAR promoter via TCF-4 response elements. Gain-of-
function mutations in the K-Ras oncogene are also found in a cells were also transfected with expression vectors for PPAR,
-/, and - and treated with increasing doses of PGE2. PGE2majority of colorectal cancers. Recently, PPAR expression and
activity were found to be significantly increased in an intestinal increased transactivation of the PPRE3-tk-luc reporter only in
cells transfected with PPAR/, but not - or - (Figure 1D),epithelial cell line conditionally immortalized with mutant K-Ras
(Shao et al., 2002). indicating that this response is specific for the PPAR/ subtype.
Similar results were obtained in the HCA-7 colorectal carcinomaAlthough the placement of PPAR downstream of key medi-
ators involved in the development of colorectal cancer is sug- cells (data not shown).
To further characterize the specificity and selectivity of thisgestive that the receptor is a tumor promoter in the intestine,
there are conflicting data in support of a direct role for the response, we tested the ability of dominant-negative PPAR
(dNPPAR) to block the increase in PPAR transcriptional acti-receptor in oncogenesis. Somatic deletion of both PPAR alleles
from an established colorectal cancer cell line results in a de- vation seen in cells treated with PGE2. The dNPPAR construct
we utilized contains an inactivating mutation in the AF-2 domaincrease in tumorigenicity (He et al., 1999). In contrast, PPAR
was shown to be dispensable for small intestinal polyp formation that encodes a receptor which retains its DNA binding domain
but lacks the ability to recruit transcriptional coactivators. PPARin Apcmin mice (Barak et al., 2002) or to attenuate polyp formation
in chemical and genetic models of colon cancer (Harman et al., constructs containing such mutations in the AF-2 domain have
been shown to be a valuable tool to specifically antagonize2004). However, one of these studies (Barak et al., 2002) was
extremely limited by the small number (n  3) of PPAR// PPAR signaling (Gurnell et al., 2000). The ability of both PGE2 and
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Figure 1. Exposure of LS174T cells to PGE2 enhances PPAR transcriptional activity
A–C: Cells were transiently transfected with PPRE3-tk-luciferase and pRL-SV40 plasmids followed by treatment with a selective synthetic PPAR agonist
GW1516 (A), PGE2, PGA2, or PGF2 (B), and cotreatment with PGE2 and GW1516 (C). The dual luciferase assays were performed as described in the
Experimental Procedures. Data are represented as the mean  S.E.M. of relative luciferase activity from three independent experiments. The data were
analyzed using the Student’s paired t test (p 	 0.05).
D: Cells were transiently cotransfected with a PPRE3-tk-luciferase/pRL-SV40 and either PPAR, PPAR, or PPAR expression plasmids, followed by treatment
with PGE2. Data are represented as the mean  S.E.M. of fold induction from three independent experiments. The relative luciferase activity of control
cells was arbitrarily set to equal 1.0; all other comparisons were relative to this standard. The data were analyzed using the Student’s paired t test (p 	
0.05).
E and F: Cells were transiently cotransfected with PPRE3-tk-luciferase/pRL-SV40 and either empty vector or dominant-negative PPAR plasmids followed by
treatment with a PGE2 (E) or a PPAR agonist (F). Data are represented as the means  S.E.M. of fold induction from three independent experiments.
the PPAR synthetic ligand GW1516 to activate endogenous binding to any of the three PPAR subtypes (Forman et al., 1997;
Kliewer et al., 1995; Yu et al., 1995). Furthermore, we have alsoPPAR activity was blocked in LS174T cells cotransfected with
dNPPAR (Figures 1E and 1F). confirmed, using the PPAR-GAL4 ligand binding reporter assay,
that PGE2 is unable to bind directly to PPAR (data not shown).At least three potential mechanisms that could explain the
ability of PGE2 to enhance PPAR transactivation were consid- It is also possible that PGE2 could increase the levels of
PPAR resulting in enhanced transactivation. However, treat-ered: (1) PGE2 directly binds to PPAR and serves as an activat-
ing ligand; (2) PGE2 upregulates PPAR expression; and (3) ment of LS174T cells with PGE2 had no effect on the protein
levels of PPAR (Figure 2A). Finally, we hypothesized that PGE2PGE2 modulates PPAR transactivation through activation of
EP receptor signaling. Certain prostaglandins have been shown may indirectly modify PPAR transcriptional activity via a MAPK
or/and the PI3K-Akt pathways, since PGE2 can activate bothto modify PPAR transcriptional activity through direct activation
of the receptor. For example, the PGD2 metabolite 15-deoxy pathways through the EP4 receptor in LS-174T cells (Sheng et
al., 2001b). For example, PGE2 induces phosphorylation of AktPGJ2 directly binds to and activates PPAR (Forman et al.,
1995; Kliewer et al., 1995). Additionally, the prostacyclin analog in a dose-dependent manner, but does not affect Akt protein
levels in LS-174T cells (Buchanan et al., 2003; Sheng et al.,carbaprostacyclin has been shown in a modified ligand binding
assay to directly bind to PPAR (Forman et al., 1997), and 2001b). PGE2-induced activation of Akt was completely blocked
by the PI3K inhibitor LY294002 (5–10 
M) (Buchanan et al.,endogenous prostacyclin production correlates with PPAR ac-
tivity (Gupta et al., 2000). It is unlikely, however, that PGE2 is a 2003; Sheng et al., 2001b). Cotreatment using PGE2 and a MAPK
inhibitor had no effect on the ability of PGE2 to increase PPARdirect ligand for PPAR. Three independent groups have pub-
lished data demonstrating that PGE2 is incapable of directly activity (data not shown). However, pretreatment of LS174T
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lary interstitial cells following hypertonic stress and in keratino-
cytes following wound injury. To determine whether PGE2 pro-
motes cell survival by increasing PPAR activity, we tested the
ability of a dNPPAR to block the antiapoptotic effect of PGE2
in the LS174T cells. Cultured LS-174T cells were treated with
increasing concentrations of PGE2 and a selective PPAR ago-
nist (GW1516) following serum deprivation. Serum starvation
resulted in significant apoptosis (28%) compared to the low
basal apoptotic rate (4%) of cells grown in 10% FBS (Figure 3A).
However, treatment with PGE2 or a PPAR agonist attenuated
apoptosis to that seen at basal levels (10% FBS conditions),
suggesting that selective PPAR activation mimics the effects
seen following PGE2 treatment (Figure 3A). To further evaluate
whether PGE2-induced cell survival requires activation of
PPAR, cells were transfected with either an empty vector or
a dominant-negative PPAR construct and then treated with
PGE2. Similar to parental cells, PGE2 decreased apoptosis in
the empty vector transfected cells, but failed to attenuate apo-
ptosis in cells expressing the dominant-negative PPAR protein
(Figure 3B). Similarly, dominant-negative PPAR also blocked
the ability of GW1516 to inhibit apoptosis, suggesting that it
was effective in blocking PPAR activation (Figure 3C). These
studies demonstrate that PGE2-mediated cell survival requires
activation of PPAR.
Next we tested the effect of giving PGE2 and GW1516 simul-
taneously on programmed cell death. We also determinedFigure 2. Mechanism by which PGE2 regulates PPAR activity
whether the PI3K pathway mediates PGE2-induced cell survival.A: PGE2 does not affect PPAR protein levels. The LS-174T cells were treated
As shown in Figure 3D, cotreatment with PGE2 and GW1516with PGE2 for 24 hr following overnight serum deprivation. PPAR protein
expression was determined by Western blot analysis. had synergistic effects on cell survival. In addition, the PI3K
B: The PI3K inhibitor LY294002 blocks PGE2-upregulated PPAR transactiva- inhibitor LY294002 reversed the ability of PGE2 to protect cellstion. Cells were transiently cotransfected with PPRE3-tk-luciferase and pRL-
from undergoing apoptosis (Figure 3D). In contrast, LY294002SV40 plasmids. The transfected cells were pretreated with either DMSO as
failed to inhibit GW1516-induced resistance to apoptosis (Figurecontrol or 5 
M PI3K inhibitor LY294002 for 1 hr before stimulation of PGE2.
Data are represented as the means  S.E.M. of fold induction from three 3D). These results further support the hypotheses that the PI3K/
independent experiments. Akt pathway mediates the effects of PGE2 on cell survival andC and D: The PI3K-Akt pathway is involved in PGE2-mediated increased that PPAR acts downstream of the PI3k-Akt pathway.PPAR transactivation. C: Cells were transiently cotransfected with PPRE3-
tk-luciferase/pRL-SV40 and either empty vector, dominant-negative Akt, or
dominant-negative PI3K plasmids followed by treatment with PGE2. D: Cells PGE2 promotes intestinal adenoma formation and cell
were transiently cotransfected with PPRE3-tk-luciferase/pRL-SV40 and either survival in Apcmin mice via PPAR
empty vector or constitutively active Akt without PGE2 treatment. Data are A large percentage of human colorectal polyps are reported torepresented as the means S.E.M. of fold induction from three independent
contain inactivating mutations in the APC gene. Thus, Apcminexperiments.
mice, in which the presence of a germline mutation in APC
results in the development of multiple polyps in the small intes-
tine, are a commonly used system to study intestinal polyposis.
cells with a specific PI3K inhibitor (LY294002) reduced PGE2- Deletion of the COX-2 gene results in decreased tumor forma-
induced PPAR transcriptional activity (Figure 2B). In addition, tion in the small intestine and colon of Apcmin and Apc716 mutant
PGE2 was unable to induce PPAR transactivation in cells tran- mice (Chulada et al., 2000; Oshima et al., 1996), suggesting
siently transfected with constructs expressing either dominant- that COX-2 derived PGs promote adenoma growth in this model
negative PI3K or Akt (Figure 2C), while the expression of consti- system.
tutively active Akt enhances PPAR transactivation in the ab- Use of stable synthetic PGE2 analogs in Apcmin mice has led
sence of exogenous PGE2 (Figure 2D). These results suggest to contradictory results (Hansen-Petrik et al., 2002; Wilson and
that PGE2 indirectly enhances PPAR transactivation via the Potten, 2000). We are not aware of any published reports de-
PI3K/Akt cascade. scribing the effects of exogenous administration of native PGE2
on adenoma formation in Apcmin mice. Apcmin mice were treated
PGE2 promotes cell survival via PPAR with vehicle (PBS) or PGE2 (150 or 300 
g/mouse twice daily).
in cultured CRC cells The body weights of mice treated with the vehicle (PBS) or PGE2
The observation that exposure of cultured CRC cells to PGE2 were comparable throughout the study. However, after 5 weeks
enhances PPAR transactivation indicates that PPAR is an of treatment, 4 of 9 mice in the PGE2-treated group (150 
g/
important downstream mediator of PGE2. PGE2 has been shown mouse/twice daily) developed rectal bleeding (data not shown).
to decrease the basal apoptotic rate in human CRC cells, and Thus, all animals were sacrificed at 13 weeks of age to avoid
undue pain and suffering. Plasma samples were analyzed foractivation of PPAR protects against apoptosis in renal medul-
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Figure 3. PPAR is required for the antiapoptotic
effects of PGE2 on LS-174T cells
A: PGE2 and a PPAR selective agonist protect LS-
174T cells from undergoing apoptosis following
serum deprivation. The cells were treated with
PGE2 as indicated or GW1516 for 3 days after
removal of serum. The number of apoptotic cells
was determined by flow cytometry using an
annexin V-FITC kit. Data are expressed as the
mean S.E.M. of percent of apoptotic cells from
three separate experiments.
B and C: Expression of a dominant-negative
PPAR protein inhibits the antiapoptotic effects
of PGE2. Cells transfected with empty vector or
dominant-negative PPAR were treated with
PGE2 (B) or the selective PPAR agonist GW1516
(C) for 3 days following serum starvation. The
apoptosis assays were performed as described
above. The top panel in B represents dominant-
negative PPARprotein expression in LS-174T cells
transfected with empty vector or dNPPAR con-
struct.
D: PGE2 and a PPAR agonist have synergistic
effects on apoptosis, and the PI3K pathway is
involved in the PGE2-induced cell survival. The
parental cells were either treated with each
agent alone (PGE2, GW1516, or LY294002) or co-
treated with a combination of PGE2 and
GW1516, PGE2 and LY294002, or GW1516 and
LY294002 for 3 days after removal of serum. The
apoptosis assays were performed as described
above.
PGE2 concentration, and the intestine (both small and large) Histologic analysis showed that large, medium, or small size
polyps in the colon represent advanced adenomas (Figures 5Awas examined to determine polyp size and number.
Mice gavaged with PGE2 (150 
g or 300 
g/mouse twice and 5B) and microadenomas (data not shown). Overall, PGE2-
treated Apcmin mice had a greater number of larger adenomasdaily) had higher PGE2 levels in plasma and intestinal tissue
than the control group (vehicle) or the group treated with a lower than the control group along the entire length of the small and
large intestine. In determining the true biological significance ofdose of PGE2 (75 
g/mouse/twice daily), demonstrating that
exogenous administration of PGE2 results in increased levels in a novel pathway, results obtained in vivo are generally consid-
ered to be much more meaningful than data obtained fromintestinal target tissues (Figure 4A). All mice gavaged with PGE2
at either 150 or 300 
g developed polyps in the large intestine, cultured cells. Thus, we examined whether PGE2 can activate
PI3K-Akt signaling in Apcmin mouse adenomas in vivo. As dem-whereas only eleven percent of control mice (1/9) developed
colorectal polyps (Figure 4B). More importantly, the average onstrated in Figure 5C, PGE2 treatment resulted in a dramatic
increase in phosphorylated Akt in adenomas from both the smallnumber of colorectal polyps per mouse at 150 and 300 
g PGE2
significantly increased (3.3  0.29 and 2.2  0.58, respectively) and large intestine by immunohistochemistry (left panel) and by
Western blot analysis (right panel). To further evaluate whethercompared to control mice (0.33  0.33) (Figure 4B). As ex-
pected, Apcmin mice in all groups developed polyps in the small PGE2 regulated apoptosis in vivo, TUNEL assays were per-
formed to detect apoptotic cells within intestinal adenomas.intestine. However, the average number of small intestinal
polyps in the control group was 50.3  5.5, and the number of The number of apoptotic cells was much lower in polyps from
mice treated with PGE2 (1 apoptotic cell/polyp) compared topolyps increased to 64.3  4.2 and 100.8  16.2, respectively,
in mice treated with either 150 or 300 
g PGE2 (Figure 4C). A that seen in control (vehicle-treated) mice (11 apoptotic cells/
polyp) (Figure 5D).similar trend was noted when measuring polyp size. The polyps
in both the small and large intestine of mice treated with either To assess the physiologic relevance of our observation that
PGE2 regulates cell survival via PPAR in cultured cells, wedose of PGE2 were significantly larger as compared to vehicle
treated mice (Figures 4D and 4E). This was especially true in determined whether PGE2 could induce polyp formation and
promote cell survival in PPAR//Apcmin mice. PPAR//Apcminthe colon (Figures 4D and 5A), where there was a dramatic
increase in large polyps (4 mm). However, the size distribution male mice were generated by conventionally crossing the
C57BL/6J-Apcmin mice with C57BL/6J- PPAR null mice. Weof the ApcMin colon polyps following treatment with 150 
g PGE2
showed a bimodal distribution (Figure 4D). These studies clearly were able to obtain 12 viable male PPAR//Apcmin mice
through an extensive breeding effort that required severalestablish that PGE2 increases colorectal and small intestinal
polyp burden in Apcmin mice. months. Six-week-old PPAR//Apcmin mice were treated for
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Figure 4. PGE2 treatment increases adenoma number and size in Apcmin mice
A: Dose response of PGE2 on prostaglandin levels in Apcmin mouse plasma (left panel) and intestinal tissues (right panel). Data are expressed as mean 
S.E.M. of vehicle (n  9), 75 
g PGE2 (n  4), 150 
g PGE2 (n  9), and 300 
g PGE2 group (n  5). Asterisks represent statistical differences (p 	 0.05;
Student’s t test).
B and C: The effect of PGE2 on polyp number in the colon or small intestine. Apcmin mice were treated with vehicle or the indicated dose of PGE2 as
described in the text. After sacrifice, the large (B) and small (C) intestines were opened longitudinally and polyps were counted using a dissecting microscope
(magnification 5). Data are expressed as mean  S.E.M. Asterisks represent statistical differences (p 	 0.05; Student’s t test).
D and E: The effect of PGE2 on polyp size in the colon or small intestine. Apcmin mice were treated with vehicle or the indicated dose of PGE2 as described
in the text. After sacrifice, the large (D) and small (E) intestines were opened longitudinally and tumor diameter was measured with a digital caliper using
a dissecting microscope (magnification 5). Data are expressed as mean  S.E.M. Asterisks represent statistical differences (p 	 0.05; Student’s t test).
seven weeks with PGE2 (300 
g/each mouse/twice daily) or and/or treatment of this disease. In fact, COX-2 inhibitors are
currently approved for use in patients with the hereditary CRCvehicle. The body weight of mice treated with vehicle or PGE2
was comparable throughout the study. Mice in the PGE2-treated syndrome familial adenomatous polyposis (FAP). For the larger
population at-risk for CRC, the therapeutic potential of COX-group were normal and had no rectal bleeding. Unlike the results
seen with wild-type Apcmin mice, administration of PGE2 failed 2 selective inhibitor therapy for either primary or secondary
prevention or as adjuvant therapy for advanced CRC is a ques-to affect colorectal polyp number (Figure 6A) or small intestinal
polyp number (Figure 6B). In addition, PGE2 treatment had no tion that has progressed beyond the laboratory and will now
largely depend on the results of multiple clinical trials currentlyeffect on the size of polyps in both colon and small intestine,
as compared with mice treated with vehicle (data not shown). in progress.
Despite these advances, there is compelling evidence toFurthermore, PGE2 failed to affect apoptosis in intestinal adeno-
mas taken from PPAR//Apcmin mice (Figure 6C). However, suggest that research on the COX-2 signaling pathway in CRC
will continue to have direct relevance to the treatment of gastro-PGE2 treatment led to increased phosphorylation of Akt in small
intestinal polyps of PPAR//Apcmin mice (Figure 6D). These intestinal malignancies (and perhaps other types of solid can-
cers as well). For example, inhibitors that target PG receptorresults demonstrate that the ability of PGE2 to promote adenoma
growth in Apcmin mice is dependent on the presence of PPAR. subtypes downstream of COX-2 could be more effective with
fewer side effects than COX-2-selective inhibitors. In addition,
use of some selective COX-2 inhibitors has been associatedDiscussion
with an increase in cardiovascular events, such as myocardial
infarctions, presumably due to an imbalance between the COX-Data obtained using cultured cells, animal models of intestinal
cancer, and humans have implicated a direct role for COX-2 in 2-derived production of PGI2 and the COX-1-derived production
of TXA2. Hence, attacking important targets downstream ofthe promotion of colorectal cancer. These studies have led to
the evaluation of COX-2 selective inhibitors for the prevention COX-2 may improve the safety profile considerably by not af-
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Figure 5. Morphologic and histologic analysis of colorectal adenomas in Apcmin mice following treatment with PGE2
A: Gross view of colonic polyps in Apcmin mice treated with vehicle or PGE2. Scale bar, 0.5 cm.
B: Histological sections of colonic polyps from Apcmin mice treated with vehicle or PGE2. Sections with 5 
m in thickness were deparaffined with xylene and
rehydrated by ethanol treatment and then stained with hematoxylin and eosin to examine intestinal adenomas. The top panel is a representative section
from vehicle treated animals, while the lower panel is a typical adenoma from PGE2-treated mice (the scale bar  50 
m).
C: PGE2 stimulates Akt activation in Apcmin mice. Sections of small (SI) and large (LI) intestine were immunostained with phospho-Akt (Ser473) antibody (left
panel). A representative section shows strong immunoreactive staining (red/brown) for phospho-Akt in the epithelial cells of polyps throughout the intestine
after treatment with PGE2 (150 
g/mouse, twice daily) for 7 weeks. Faint staining was observed in the small intestinal adenomas, and very weak staining
was found in normal colonic tissue of vehicle-treated mice. Scale bar, 100 
m. The right panel of C represents the levels of phospho-Akt and Akt in the
small intestinal adenomas taken from mice treated with either vehicle or PGE2 (150 or 300 
g/mouse). Each sample included 40 polyps collected from
two animals.
D: TUNEL staining of an intestinal adenoma taken from mice treated with vehicle (left panel) or PGE2 (right panel). Apoptotic nuclei are stained dark brown
by the DeadEnd colorimetric TUNEL system as described in the Experimental Procedures. The arrows denote a group of TUNEL-positive stained epithelial
cells undergoing apoptosis. Scale bar, 100 
m.
fecting the balance of prostaglandins important for regulating plex interaction, activates RXR signaling only in the presence
vascular tone and platelet aggregation. of PPAR but not in the presence of - or - subtypes. We
PGE2 is the major prostaglandin product of the cyclooxygen- completed experiments which demonstrated that PGE2 treat-
ase pathway found in many solid tumors, including CRC. How- ment had no effect on RXR activity to rule out this possibility
ever, the role of PGE2 in promoting intestinal tumor growth (data not shown).
remains controversial. Therefore, we have focused on determin- Nuclear hormone receptor activity is regulated by a number
ing the key downstream signaling molecules responsible for of different variables in a complex set of interactions. Most
regulating adenoma growth. simplistically, a receptor can be activated by the addition of an
activating ligand. Multiple reports have shown in ligand binding
Regulation of PPAR transcriptional activity by PGE2 assays that PGE2 has no binding affinity for any of the threeExposure of CRC cells to PGE2 results in a dose-dependent PPAR subtypes. We have confirmed these results using the
increase in PPAR transcriptional activity. The effect is specific
PPAR-GAL4 ligand binding reporter assays. We did not observefor the PPAR/ subtype, based on the finding that it was only
any increase in PPAR binding activity in the PPAR-LBD-GAL4seen when cells were transfected with PPAR but not PPAR
binding reporter assays following prolonged treatment of cellsor PPAR. Moreover, expression of a dominant-negative PPAR
with PGE2 (data not shown), indicating the lack of PGE2 bindingprotein blocked the ability of PGE2 to modulate PPAR activity.
or induction of an endogenous ligand. We did show that theHowever, PPARs form obligate heterodimers with the RXR fam-
ability of PGE2 to regulate PPAR is dependent on the PI3K/Aktily of nuclear receptors. Further, the PPRE3-tk-luciferase re-
kinase pathway. How the PI3K/Akt pathway regulates PPARporter gene can be activated by changes in RXR activity. Thus,
there is a possibility that PGE2, in some type of unknown com- activity will be addressed in the future.
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Figure 6. PGE2 has no effect on adenoma num-
ber in Apcmin mice lacking PPAR
A and B: Six-week-old PPAR//Apcmin mice were
treated with vehicle (n  6) or the PGE2 (n  6)
as described in the text. After sacrifice, the large
(A) and small (B) intestines were opened longitu-
dinally and polyps were counted using a dis-
secting microscope (magnification 5). Data
are expressed as mean  S.E.M. Asterisks repre-
sent statistical differences (p 	 0.05; Student’s t
test).
C: TUNEL staining of intestinal adenomas from
PPAR//Apcmin mice treated with vehicle (left
panel) or PGE2 (right panel). Scale bar, 100 
m.
D: Western blot analysis of phospho-Akt and Akt
in the small intestinal polyps taken from PPAR//
Apcmin mice treated with either vehicle or PGE2
(300
g/mouse). Each sample includes 40 polyps
collected from two animals.
PGE2 regulation of apoptosis and intestinal polyp family. To our knowledge, no one has generated data testing
whether native PGE2 has an effect on intestinal adenoma growth.growth is dependent on PPAR
We have shown both in vitro and in vivo that the ability of PGE2 Our results establish that treatment with the endogenous form
of PGE2 has pro-oncogenic activity in an in vivo model system.to promote resistance to apoptosis and to accelerate intestinal
adenoma growth is dependent on PPAR. The addition of either Most importantly, the ability of PGE2 to both inhibit apoptosis
and increase intestinal polyp growth is essentially negated inPGE2 or GW1516 (a selective PPAR agonist) attenuates growth
factor withdrawal-mediated apoptosis in cultured CRC cells. Apcmin mice that are genetically null for PPAR, although PGE2
still induces activation of Akt in small intestinal adenomas ofFurther, expression of a dominant-negative PPAR protein
blocks the ability of PGE2 to promote cell survival. Using a these animals.
The role of PPAR in CRC is not well understood. Althoughdominant-negative approach has a number of caveats. For ex-
ample, the introduction of dominant-negative PPAR could have activation of the receptor using a synthetic agonist promotes
intestinal adenoma growth, genetic loss-of-function experi-multiple biological effects independent of its ability to inactive
endogenous PPAR activity. To overcome these limitations, we ments in different model systems continue to produce variable
results. Deletion of PPAR from an established CRC cell linetested the importance of our in vitro findings in a physiologically
relevant in vivo model system. causes a reduction in tumorigenic potential (Park et al., 2001).
However, experiments that examine polyp formation in PPAR//Apcmin mice spontaneously develop intestinal adenomas;
however, these occur mainly in the small intestine, with very Apcmin animals have found either no effect (Barak et al., 2002)
or, paradoxically, an increase in polyp number and size (Harmanfew in the colon. A recent report showed that Apcmin mice have
higher levels of PGE2 than the wild-type mice at 15 weeks of et al., 2004). The explanation for these disparate results may
relate to inherent differences in model systems (an establishedage (Kettunen et al., 2003). After 15 weeks, the concentration
of PGE2 correlates well with the number of polyps (Kettunen et cancer cell line versus developing adenomas) or to the particular
background strain of PPAR null mice being evaluated. We haveal., 2003). Treatment of Apcmin mice with PGE2 leads to a 2- to
3-fold increase in PGE2 concentrations in both the serum and noted that the number of adenomas which develop in Apcmin
mice is quite variable, depending on the background strain andintestine compared to vehicle alone (Figure 1). This increase is
comparable to that seen when comparing 15-week-old wild- fat content of the diet. Our results using Apcmin mice null for
PPAR support the view that PPAR is pro-oncogenic in thistype and Apcmin mice. Furthermore, PGE2 treatment promotes
a significant increase in polyp size in both the small and large model system. Why we see results contrary to prior studies may
be due to differences in the genetic background of Apcmin miceintestine. Prior studies examining the effects of exogenous PGE2
administration on tumor growth have relied on synthetic analogs or possibly to differences in the type of targeting strategy em-
ployed to delete PPAR.that have differential activity for members of the EP receptor
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1994). The levels of PGE2 in the plasma and tissue were quantified usingThe mechanism by which PPAR regulates cell survival in
gas chromatography negative ion chemical ionization mass spectrometryCRC cells is not known. Recent studies have convincingly estab-
as described (DuBois et al., 1994). The concentration of PGE2 in the sampleslished that PPAR promotes cell survival in keratinocytes (Di-
was calculated by comparing the ratios of its peak areas to the internal
Poi et al., 2002; Michalik et al., 2001). In these experiments, standard.
ablation of PPAR in vivo resulted in increased apoptosis in the
mouse epidermis. The receptor was found to regulate a number Cell culture and reagents
LS-174T cells were purchased from ATCC (Manassas, VA) and maintainedof important apoptotic-related genes, including several mem-
in McCoy’s 5A medium with 10% fetal bovine serum. Ly 294002 was ob-bers of the caspase family. The same group subsequently dem-
tained from Calbiochem (La Jolla, CA). PGE2, PGA2, and PGF2 were pur-onstrated that PPAR promoted cell survival via activation of
chased from Cayman Chemical (Ann Arbor, MI). GW1516 was obtainedAkt1. Our data indicating that the PI3K/Akt pathway also upreg-
from CareX (Strausburg, France). The constructs of constitutively active Akt
ulates PPAR activity suggest that a positive feedback loop (myristylated form of Akt1), dominant-negative Akt (kinase-deficient mutants
might exist between PPAR and Akt to regulate apoptosis under of Akt1-K179M), and dominant-negative PI3K (pSG5-p85) were described
previously (Sheng et al., 2001a).certain physiological conditions. Whether the apoptotic-related
target genes of PPAR in keratinocytes are the same as those
TUNEL assaysregulated by the receptor in intestinal epithelial cells is not
The fragmented DNA of apoptotic cells in tissue sections was end-labeledknown.
using the Dead-End colorimetric TUNEL system according to the manufac-
In summary, our results provide evidence that PGE2 pro- turer’s instructions (Promega, Madison, WI). Sections were deparaffinized,
motes intestinal adenoma formation via PPAR. Previous stud- rehydrated, incubated with 20 
g/ml proteinase K, washed with PBS, and
ies have documented that PPAR is also downstream of the then immersed in a TDT reaction mixture for 60 min at 37C. The slides were
then washed in 2 SSC for 15 min to stop the reaction. Following anotherWnt/-catenin and K-Ras pathways in CRC cells. Our data link-
wash and blocking cycle, the slides were incubated with Streptavidin peroxi-ing the COX pathway to PPAR suggest that the receptor is an
dase for 30 min at room temperature and then stained with DAB.integral component of the crosstalk that occurs between multi-
ple pro-oncogenic signaling pathways during the shift in balance
Immunohistochemical staining
between cell survival and cell death that promotes colorectal Tissue sections (5 
m thick; n  5 per animal) were stained with a rabbit
carcinogenesis. Activators of PPAR have hypolipidemic ef- polyclonal antibody against phospho-Akt (Ser473) at a dilution of 1:250 (Cell
fects, and compounds that activate the receptor are currently Signaling, Beverly, MA). The immunohistochemical staining was completed
by using a Zymed-Histostain-SP Kit (Zymed, South San Francisco, CA) asin large-scale clinical trials to examine their potential use for the
described previously (Gupta et al., 2004).treatment of patients with hyperlipidemic states. Our results
would suggest that PPAR is an important pro-oncogenic factor
Stable transfection and Western blotin CRC, and that agonists of the receptor may have proneoplas-
The LS-174T cells were transfected with 0.4 
g empty vector, dominant-
tic side effects in certain populations at risk for CRC (particularly negative PPAR by the LipofectAMINE Plus reagent according to the manu-
those cancers initiated by loss of function mutations in APC). facturer’s protocol (Life Technologies, Inc., Rockville, MA). Stable transfec-
As a corollary, antagonists of the receptor might prove to be tants were selected by growth in zeocin (Invitrogen, Carlsbad, CA). Whole cell
extracts were prepared from parental LS-174T cells expressing a dominant-useful in the chemoprevention and/or treatment of CRC.
negative PPAR protein or empty vector-transfected cells treated with vehi-
cle or PGE2 for 24 hr. For Western blot analysis, the cells or polyps takenExperimental procedures
from the intestine were washed at 4C with 1 PBS and lysed in 0.6 ml of
RIPA buffer containing protease inhibitor tablets (Boehringer MannheimAnimals
Corp., Indianapolis, IN). Fifty micrograms of soluble protein was boiled,C57BL/6J-Apcmin male mice were obtained from Jackson Laboratory (Bar
subjected to electrophoresis on a 10% SDS-PAGE reducing gel, and thenHarbor, ME) at five weeks of age. C57BL/6J-Apcmin and C57BL/6J-Apcmin/
electrophoretically transferred to a 0.2 
m nitrocellulose membrane (Bio-PPAR/ were housed and fed with standard mouse diet in the Animal Care
Rad, Hercules, CA). The membrane was blocked with 5% dry milk in TBS-TFacility according to National Institutes of Health and institutional guidelines
buffer for 1 hr and then incubated for 12–16 hr at 4C in a 1:500 dilution offor laboratory animals. At the age of 6 weeks, Apcmin mice (n  26) were
the PPAR antibody (Perseus Peoteomics Inc., Japan), Akt, or phospho-Aktrandomly grouped into four groups according to the PGE2 treatments (vehi-
antibody (Cell Signaling, Beverly, MA) in TBS-T buffer which contained 5%cle, 75 
g PGE2/each mouse, 150 
g PGE2/each mouse, and 300 
g PGE2/
dry milk. After three washes with TBS-T buffer, the membrane was incubatedeach mouse), and PPAR//Apcmin mice (n  12) were randomly grouped
in a 1:3000 dilution of the anti-mouse or anti-rabbit immunoglobulin conju-into two groups treated with vehicle or 300 
g PGE2/each. Vehicle or differing
gated with horseradish peroxidase (Boehringer Mannheim Corp.) for 1 hr atamounts of PGE2 in 100 
l sterile PBS was administered twice daily via
room temperature. After three washes with TBS-T buffer, the protein bandsgavage feeding. After treatment for 7 weeks, mice were sacrificed. Blood
were detected with the ECL Western blotting detection reagents (Amershamand entire intestinal tissues were collected from mice in each group for
Pharmacia Biotech, Piscataway, NJ) according to the manufacturer’s in-analysis of levels of PGE2. The entire intestines were then immediately flushed
structions.with ice-cold PBS (pH 7.4) and filled with 10% neutral buffered formalin for
24 hr. The intestines were transferred to 70% ethanol for 24 hr, opened
Apoptosis assayslongitudinally, and examined under a magnification dissecting microscope
Parental LS-174T cells, dominant-negative PPAR cells, or cells transfected(magnification 5) to count polyps. The tumor diameter was measured with
with empty vector (2.5  105/each well) were plated in 6-well plates. Aftera digital caliper. After tumors were counted, intestinal tissues were fixed flat
culture overnight, the cells were washed twice with PBS and then incubatedon the sheets of filter paper and embedded in paraffin. For histology, sections
in serum-free media containing either 10% FBS, vehicle, LY294002, PGE2,with 5 
m in thickness were deparaffined with xylene and rehydrated by
and/or GW1516 for 3 days. For the PGE2 experiments, the culture mediaethanol treatment and then stained with hematoxylin and eosin to examine
was replaced with fresh serum-free media containing PGE2 every 24 hr. Theintestinal adenomas. The unstained sections were subjected to TUNEL
assays for apoptotic cells were performed using a TACS Annexin V-FITCassays and immunohistochemical staining.
Apoptosis Detection Kit according to the manufacturer’s instructions (R&D
System, Inc., Minneapolis, MN). For this assay, the cells were harvested,PGE2 levels
Intestinal tissues were homogenized and PGE2 was acidified and extracted washed, and then incubated with Annexin V-FITC and propidium iodide.
The cells were again washed and then analyzed by flow cytometry. Thefrom the homogenate and plasma as previously described (DuBois et al.,
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human colorectal adenomas and adenocarcinomas. Gastroenterology 107,combination of Annexin V-FITC and propidium iodide allowed for the differ-
1183–1188.entiation between early apoptotic cells (Annexin V-FITC positive), late apo-
ptotic cells (Annexin V-FITC and propidium iodide positive), necrotic cells Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., and
(propidium iodide positive), and viable cells (both negative). Evans, R.M. (1995). 15-Deoxy- 12, 14-prostaglandin J2 is a ligand for the
adipocyte determination factor PPAR gamma. Cell 83, 803–812.
PPAR transcriptional assays
Forman, B.M., Chen, J., and Evans, R.M. (1997). Hypolipidemic drugs, poly-The LS-174T cells (2.0 105/well in 12-well plates) were transiently cotrans-
unsaturated fatty acids, and eicosanoids are ligands for peroxisome prolifer-fected with 0.3 
g PPRE3-tk-luciferase/5 ng of pRL-SV40 and 0.4 
g of
ator-activated receptors  and . Proc. Natl. Acad. Sci. USA 94, 4312–4317.empty vector, PPAR, PPAR, PPAR, dominant-negative PPAR, domi-
nant-negative Akt, constitutively active Akt, or dominant-negative PI3K plas- Giardiello, F.M., Casero, R.A., Jr., Hamilton, S.R., Hylind, L.M., Trimbath,
mids using LipofectAMINE Plus reagent according to the manufacturer’s J.D., Geiman, D.E., Judge, K.R., Hubbard, W., Offerhaus, G.J., and Yang,
instructions (Life Technologies, Inc., Rockville, MA). After a 3 hr incubation, V.W. (2004). Prostanoids, ornithine decarboxylase, and polyamines in pri-
fresh media without serum was added, and the cells were incubated for an mary chemoprevention of familial adenomatous polyposis. Gastroenterology
additional 4 hr. These cells were then treated with either vehicle, GW1516, 126, 425–431.
and/or PGE2 for 16 hr. For experiments evaluating a PI3K inhibitor, cells
Gupta, R.A., and DuBois, R.N. (2001). Colorectal cancer prevention andwere pretreated with Ly294002 for 1 hr before treatment with vehicle or
treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11–21.PGE2 16 hr. Following the experiment, the cells were harvested and lysed.
Luciferase activity was measured using a Dual Luciferase kit (Promega) and Gupta, R.A., Tan, J., Krause, W.F., Geraci, M.F., Willson, T.M., Dey, S.K., and
a Monolight 3010 luminometer (BD Biosciences/Pharmingen, San Diego, DuBois, R.N. (2000). Prostacyclin-mediated activation of PPAR in colorectal
CA). The relative luciferase activity was determined and normalized to Renilla cancer. Proc. Natl. Acad. Sci. USA 97, 13275–13280.
luciferase.
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